Technology Veteran to Enhance Operations as AI Healthcare Analytics Platform Expands
NEW YORK & SAN FRANCISCO, September 04, 2025–(BUSINESS WIRE)–Komodo Health, a frontrunner in AI-driven healthcare intelligence, has officially appointed Miles Ennis as the new Chief Operating Officer (COO). Ennis, who originally joined the company as Chief Revenue Officer in July 2024, will now broaden his leadership responsibilities to manage the operational strategy and execution across all sectors of the business while continuing to foster commercial success. This development comes as Komodo Health seeks to scale its capabilities in response to the rising demand for its innovative AI solutions, including Marmot™—its proprietary AI engine designed to assist Life Sciences organizations in addressing intricate questions with exceptional speed and accuracy. Enhancing operational capabilities is essential to support the rapid growth and deployment of their platform among enterprise customers.
Since his arrival at Komodo, Ennis has significantly contributed to the company’s achievements, steering the revenue organization to consistently exceed business goals and forging strategic alliances that have widened Komodo’s market presence. Notably, he has played a crucial role in establishing a pioneering partnership with Nasdaq, which marks the first time healthcare intelligence is being integrated into the Financial Services sector. This collaboration allows hedge funds, private equity, and venture capital firms to make better-informed investment choices by leveraging insights from Komodo’s Healthcare Map®, which tracks the healthcare journeys of over 330 million patients across the United States.
“Since joining us, Miles has made an immediate and meaningful impact,” stated Web Sun, President and Co-Founder of Komodo Health. “During his tenure as CRO, he has not only achieved remarkable commercial outcomes but has also showcased the strategic insight and operational discipline necessary to elevate our organization. His promotion to COO is a logical advancement that enables him to enhance our operations and provide exceptional value to our clients.”
As COO, Ennis will oversee company-wide operations, which encompass Revenue, Services, Account Management, Customer Success, Consulting, and Strategic Programs. He will also work to enhance cross-functional collaboration across Product Engineering, Marketing, and Technology. Ennis will focus on aligning Komodo’s workforce, processes, and platforms to promote growth, improve service delivery, and solidify the company’s standing as a leader in healthcare analytics powered by AI.
“I am privileged to step into this expanded role at such a pivotal moment in Komodo’s journey,” remarked Ennis. “My priority will be to develop the operational framework essential for scaling our AI platform across international markets, while ensuring we maintain the speed and accuracy our clients expect. As we ramp up Marmot deployment and venture into new market segments, operational excellence will be crucial in fulfilling our goal of alleviating the burden of disease.”
Ennis brings over two decades of experience in expanding global teams and spearheading digital transformation in leading technology firms, including Talkdesk, IBM, Cisco, and Aspen Technology. His proficiency in complex commercial operations and strategic growth has played a vital role in Komodo’s ongoing market development.
About Komodo Health
Komodo Health stands at the forefront of healthcare intelligence, developing the foundational AI that is set to revolutionize how Life Sciences and healthcare organizations uncover, develop, and deliver patient care. By implementing Marmot, its exclusive AI engine, within its Healthcare Map—recognized as the most authoritative and high-fidelity platform for real-world de-identified patient insights—Komodo is transforming the landscape of slow, disjointed analyses. The company’s healthcare-native AI platform allows for the rapid and rigorous answering of complex questions, accelerating critical decisions throughout the product life cycle—from trial design to launch strategy to post-market evidence generation—ultimately aiming to reduce the burden of disease.
